<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>152</volume><submitter>Liang A</submitter><funding>Western University Schulich School of Medicine &amp;amp;amp; Dentistry</funding><pubmed_abstract>&lt;h4>Objective&lt;/h4>To explore qualitatively the relationship between selected trial design choices and proxies for a scientific and clinical uptake in a cohort of published randomized controlled trials (RCTs) of corticosteroids for COVID-19, to identify design characteristics that may result in trials with potential to eliminate equipoise, achieve uptake, and help reduce research waste.&lt;h4>Study design and setting&lt;/h4>A systematic literature search and qualitative, narrative review of published RCTs (up to April 13, 2021) evaluating the effectiveness of systemic corticosteroids in treatment of COVID-19. We extracted information on sample size, number of centers, single-country or multi-country conduct, dates of initiation and of publication, risk of bias and pragmatism scores, and also on a</pubmed_abstract><journal>Journal of clinical epidemiology</journal><pagination>116-124</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9536028</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>The relationship between pragmatism, timing, and study size on impact of randomized trials: a qualitative, hypothesis generating study of trials of systemic corticosteroids for COVID-19.</pubmed_title><pmcid>PMC9536028</pmcid><pubmed_authors>Deng XD</pubmed_authors><pubmed_authors>Liang A</pubmed_authors><pubmed_authors>Cirone KD</pubmed_authors><pubmed_authors>Zwarenstein M</pubmed_authors></additional><is_claimable>false</is_claimable><name>The relationship between pragmatism, timing, and study size on impact of randomized trials: a qualitative, hypothesis generating study of trials of systemic corticosteroids for COVID-19.</name><description>&lt;h4>Objective&lt;/h4>To explore qualitatively the relationship between selected trial design choices and proxies for a scientific and clinical uptake in a cohort of published randomized controlled trials (RCTs) of corticosteroids for COVID-19, to identify design characteristics that may result in trials with potential to eliminate equipoise, achieve uptake, and help reduce research waste.&lt;h4>Study design and setting&lt;/h4>A systematic literature search and qualitative, narrative review of published RCTs (up to April 13, 2021) evaluating the effectiveness of systemic corticosteroids in treatment of COVID-19. We extracted information on sample size, number of centers, single-country or multi-country conduct, dates of initiation and of publication, risk of bias and pragmatism scores, and also on a</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Oct</publication><modification>2025-04-22T09:52:28.824Z</modification><creation>2025-02-19T01:08:00.169Z</creation></dates><accession>S-EPMC9536028</accession><cross_references><pubmed>36209914</pubmed><doi>10.1016/j.jclinepi.2022.09.018</doi></cross_references></HashMap>